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Negative symptom measurementGuidance for selection of instruments for measurement of negative symptoms is rapidly evolving. As there
are continuing advances in the description of negative symptoms, new instruments are under development,
and new data on the performance of instruments emerge from clinical trials.
The Scale for Assessment of Negative Symptoms (SANS), the Positive and Negative Syndrome Scale (PANSS),
the Marder Negative Factor and the Negative Symptom Assessment-16 (NSA-16) are considered to be reli-
able and valid measures for negative symptom trials but differ with respect to their domain coverage, use
of informants, integration of global scores, administration time and comprehensiveness of their structured
interviews. In response to the 2005 NIMH–MATRICS consensus statement, work groups are ﬁeld testing
and reﬁning two new measures, the Clinical Assessment Interview for Negative Symptoms (CAINS) and
the Brief Negative Symptom Scale (BNSS). Both address the ﬁve currently recognized domains of negative
symptoms, differentiate appetitive from consummatory aspects of anhedonia and address desire for social re-
lationships. Thus far, both have exhibited promising psychometric properties.
© 2013 The Author. Published by Elsevier B.V.Open access under CC BY-NC-ND license.Guidance for the selection of instruments for measurement of nega-
tive symptoms is rapidly evolving. As there are continuing advances in
the description of negative symptoms, new instruments are under
development, and new data on the performance of instruments emerge
from clinical trials.
The 2005 NIMH–MATRICS consensus statement on negative symp-
toms recommended the use of the Schedule for Assessment of Negative
Symptoms (SANS) or Positive and Negative Syndrome Scale (PANSS)
but noted weaknesses in both scales. The statement recommended
that a workgroup develop and test a new instrument for clinical trials
that would address all the currently recognized domains of negative
symptom functioning, distinguish appetitive and consummatory as-
pects of anhedonia and assess a subject's desire for relationships
(Kirkpatrick et al., 2006).
In 2009, representatives of academia, the pharmaceutical industry
and the US Food and Drug Administration met in a workshop format
under the auspices of the International Society for Clinical Trials
Methodology (ISCTM) to update the 2005 recommendations (Marder
et al., 2011). The consensus was that the Negative Symptom Assess-
ment Scale (NSA-16) along with the SANS and subscales of the PANSS
were reliable and valid measures of negative symptoms for clinicalV.Open access under CC BY-NC-ND licetrials. The workshop expressed preference for the PANSS negative fac-
tors derived from factor analyses over the original PANSS negative
subscale.
Although the SANS, PANSS negative factors and NSA-16 perform
adequately psychometrically, the scales differentiate in important
ways that may impact their ﬁt to clinical trials (Tables 1 and 2). Varia-
tions among the scales in coverage of the ﬁve negative symptom
domains identiﬁed in the 2005 NIMH–MATRICS consensus statement
are shown in Table 1. The domains represent areas of normal function-
ing in expression, motivation and pleasure that are impaired in schizo-
phrenia. The evaluation of each domain is important because it is
unknown whether their underlying pharmacologies are the same or
different and thereforewhether theymight respond to treatment in dif-
ferent manners (Kirkpatrick et al., 2006). Only the SANS includes all 5
recommended domain items. However, the SANS also addresses atten-
tion, a domain considered to be outside of negative symptoms, andmin-
gles the assessment of anhedonia and asociality. The original PANSS
negative symptom subscale contains two items, “stereotyped thinking”
and “difﬁculty in abstract thinking,” which are outside the currently
recommended negative symptom domains. The PANSS Marder nega-
tive factor does not include these items. Neither the NSA-16 nor the
PANSSMarder negative factor directly addresses the negative symptom
domain, anhedonia. Other PANSS negative factor solutions exist as well
(for a review, see Levine and Rabinowitz, 2007).
The 2009 ISCTM workgroup recommended the use of a global
negative symptoms measure in addition to a negative symptom
rating scale. The SANS, PANSS and NSA-16 differ in this respect as
well. Only the NSA-16 provides a distinct item rating a global measure
of negative symptoms. The SANS items assess global scores separatelynse.
Table 1
Comparative domain coverage.
NIMH–MATRICS domains SANS domains NSA-16 domains PANSS Marder Factor
Blunted affect Affective ﬂattening or blunting Emotional/affective dysfunction N1, blunted affect
Alogia Communication dysfunction
Alogia N6, lack of spontaneity and conversation ﬂow
Asociality Dysfunction in sociality
Anhedonia-asociality N4, passive apathetic social withdrawal
G16, active social avoidance
N3, poor rapport
Anhedonia
Avolition Motivational dysfunction
Avolition-apathy N2, emotional withdrawal
G7, motor retardation
Attention
Reduced psychomotor activity G7, motor retardation
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score for the SANS may also be calculated but is not part of the scale
proper. The PANSS Marder negative factor does not include a global
items measure. The Clinical Global Impression Schizophrenia Scale
(Negative subscale) (Haro et al., 2003) is sometimes used in industry
trials as a global measure of negative symptoms to accompany scales
that do not incorporate global scores of their own.
The PANSS differs from the SANS and NSA-16 in that informant
roles are explicitly described for many items and are the sole basis
of rating for 2 of the negative factor items. (Kay et al., 2006). The
NSA-16 instruction manual encourages awareness of informant infor-
mation and resolution of any conﬂicts with information provided by
the patient (Alphs, 2006). The Comprehensive Assessment of Symp-
toms and History (CASH), which incorporates the SANS, recommends
the use of informant information when needed, and corroborative
history from family members has been shown to improve assessment
of negative symptoms by the SANS (Ho et al., 2004). However, only
the PANSS explicitly requires informant information for completion.
Suggested interview questions and prompts are built into the
SANS and the instruction manual of the NSA-16. Two extensive
clinician-administered structured instruments for interviewing the
patient (SCI-PANSS) and informant (IQ-PANSS), respectively, are
available for the PANSS.
A survey of 39 US raters participating in a negative symptoms trial
found no difference in perceptions of clarity of anchor points among
the SANS, PANSS and NSA-16. However, the NSA-16 was viewed as
the most effective measure of negative symptoms and the PANSS as
the least (F(2,82) = 3.53, p b 0.05) (Daniel et al., 2011b). In training
contexts for international clinical trials, it appears possible to obtain
relatively high levels of agreement among investigators in rating nega-
tive symptoms with the NSA-16, the PANSS negative subscale and the
PANSS Marder negative factor (Daniel et al., 2011a). Adequate data to
compare sensitivity to change among the PANSS negative subscale,Table 2
Comparative scale description.
SANS⁎ PANSS⁎⁎ NSA-16⁎⁎⁎ BNSS CAINS
Items 25 30 16 13 13
Likert-type scale (range) 0–5 1–7 1–6 0–6 0–4
Estimated time (min.) 30 30–40 20–30 15 30
Structured interview available Yes Yes Yes Yes Yes
Explicit anchor points Yes Yes Yes Yes Yes
Informant required ⁎⁎⁎⁎ No Yes No No No
Global score per domain Yes No No No No
Overall global/summary scores Yes No Yes No No
⁎ Includes 5 global items.
⁎⁎ Three supplemental items also available.
⁎⁎⁎ Includes 1 global item.
⁎⁎⁎⁎ Although not explicitly required by each scale, informant use is recommended
when helpful.PANSSMarder negative factor, NSA-16 and SANS in predominant, persis-
tent negative symptom double-blind, placebo-controlled international
clinical trial contexts are not yet available. However, potentially informa-
tive trials are in progress.1. New instruments
The 2005 NIMH–MATRICS consensus statement on negative
symptoms recommended the development and testing of a new
instrument for clinical trials that would address the ﬁve currently
recognized domains of negative symptom functioning (blunted affect,
alogia, asociality, anhedonia and avolition), distinguish appetitive and
consummatory aspects of anhedonia and assess a subject's desire for
relationships (Kirkpatrick et al., 2006). In the interim, two separate
new negative symptom scales, the Brief Negative Symptom Scale
(BNSS) and the Clinical Assessment Interview for Negative Symptoms
(CAINS) (Forbes, Blanchard et al., 2010; Kirkpatrick et al., 2011, respec-
tively), have been developed. They are contrasted with each other and
the PANSS, SANS and NSA-16 in Table 2. The BNSS and CAINS each
address all 5 negative symptomdomains and thus far have demonstrat-
ed mostly promising inter-rater and test–retest reliability, convergent
and divergent validity and functional correlations (Forbes, Blanchard
et al., 2010; Horan et al., 2011; Kirkpatrick et al., 2011; Strauss et al.,
2012a; Kring et al., 2013). Clinical trials experience and assessment of
sensitivity to change has not yet been reported. Both scales are expected
to undergo additional ﬁeld testing, reﬁnement and psychometric
characterization and are potentially subject to further revision.
Consistent with the 2005 NIMH–MATRICS recommendations and
unlike the PANSS, SANS and NSA-16, the BNSS and CAINS differenti-
ate experience of pleasure during the rating period vs. the expecta-
tion of pleasure in the future. Unlike the blunted affect item of the
PANSS, the BNSS and CAINS use separate items to measure facial
expression, vocal expression and expressive gestures. Neither scale
includes a global assessment.
The BNSS has 13 items (Table 3). The principal component factor
analysis with maximum likelihood rotation resulted in two factors:Table 3
BNSS items.
Anhedonia/avolition/asociality factor Expressivity factor
Item Item
Anhedonia/intensity of pleasure Blunted affect/facial expression
Anhedonia/frequency of pleasure Blunted affect/vocal expression
Anhedonia/intensity of expected pleasure Blunted affect/expressive gestures
Distress Alogia/quantity of speech
Asociality/behavior Alogia/spontaneous elaboration
Asociality/internal experience
Avolition/behavior
Avolition/internal experience
Table 4
CAINS items.
MAP scale EXP scale
Item Item
Motivation for close
family/spouse/partner relationships
Blunted affect/facial expression
Motivation for close friendships and
romantic relationships
Blunted affect/vocal expression
Frequency of pleasurable social
relationships—past week
Blunted affect/expressive gestures
Frequency of expected pleasurable social
relationships—next week
Alogia/quantity of speech
Motivation for work and school activities
Frequency of expected pleasurable work
and school activities—next week
Motivation for recreational activities
Frequency of pleasurable recreational
activities—past week
Frequency of pleasurable recreational
activities—next week
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(Strauss et al., 2012b). The BNSS includes a lack of normal distress
item, which had moderate loading on the emotional expressivity
factor. For asociality and avolition, the BNSS questions address
behavior separately from internal experience. The authors indicate
the interview can be completed in 15 min. (Strauss et al., 2012a).
The CAINS has 13 items divided into a 9-item motivation and
pleasure subscale (MAP) and a 4-item expression subscale (EXP)
(Table 4). Similar to the BNSS, a two-factor solution broadly differen-
tiated items based on reports of motivation, emotion or closeness
from expression items based on observations of behavior (Kring et
al., 2012). Motivation items address both behavior and internal
experience. The authors have made training manuals and videos
available online at http://www.med.upenn.edu/bbl/downloads/
CAINSVideos.shtml.
Given the relatively early stage of development of the CAINS and
BNSS, it is likely that in clinical trials contexts they will be used in
conjunction with the PANSS, SANS or NSA-16 until their properties
are better deﬁned. Data comparing the psychometric performance
of the BNSS and CAINS in the same population are not yet available.
2. Summary
The SANS, PANSS negative factor and NSA-16 are considered to be
reliable and valid measures for negative symptom trials but differ
with respect to their domain coverage, use of informants, integration
of global scores, administration time and comprehensiveness of their
structured interviews. In response to the 2005 NIMH–MATRICS consen-
sus statement, work groups are ﬁeld testing and reﬁning the CAINS
and BNSS, two new measures that address the ﬁve currently recog-
nized domains of negative symptoms, differentiate appetitive from
consummatory aspects of anhedonia and address desire for socialrelationships. Thus far, both have exhibited promising psychometric
properties. Future clinical trial experience in negative symptom pop-
ulations will provide data on the relative sensitivity to change and
global suitability of the BNSS and CAINS vs. each other and the earlier
generation scales.
Role of the funding source
The employer, Bracket Global, LLC, provided the funding.
Contributors
None except the author.
Conﬂict of interest
David G. Daniel is a full-time employee of Bracket Global, LLC.
Acknowledgments
The author gratefully acknowledges Lisa and Beverly Daniel for editorial assistance.
References
Alphs, L., 2006. Negative Symptom Assessment 16 (NSA-16) Instruction Manual.
Andreasen, N.C., 1984. Scale for the Assessment of Negative Symptoms (SANS). University
of Iowa, Iowa City, Iowa.
Daniel, D.G., Alphs, L., Cazorla, P., Bartko, J.J., Panagides, J., 2011a. Training for assessment
of negative symptoms of schizophrenia across languages and cultures: comparison of
the NSA-16 with the PANSS Negative Subscale and Negative Symptom factor. Clin.
Schizophr. Relat. Psychoses 5, 87–94.
Daniel, D.G., Velligan, D., Greco, N., Bartko, 2011b. Comparing measures of negative
symptoms of schizophrenia in clinical trials: the investigators' view. Poster
presented at the 7th Annual International Society for Clinical Trials Methodology
(ISCTM) Scientiﬁc Meeting Washington, DC on February 21-23, 2011.
Forbes, C., Blanchard, J.J., Bennett, M., Horan, W.P., 2010. Initial development and pre-
liminary validation of a new negative symptom measure: The Clinical Assessment
Interview for Negative Symptoms (CAINS). Schizophr. Res. 124, 36–42.
Haro, J.M., Kamath, S.A., Ochoa, S., Novick, D., Rele, K., Fargas, A., Rodriguez, M.J., Rele,
R., Orta, J., Kharbeng, A., Araya, S., Gervin, M., Alonso, J., Mavreas, V., Lavrentzou,
E., Liontos, N., Gregor, K., Jones, P.B., 2003. The Clinical Global Impression–Schizophrenia
scale: a simple instrument to measure the diversity of symptoms present in
schizophrenia. Acta Psychiatr. Scand. Suppl. 416, 16–23.
Ho, Beng-Choon, Flaum, M., Hubbard, W., Arndt, S., Andreasen, N.C., 2004. Validity of
symptom assessment in psychotic disorders: information variance across different
sources of history. Schizophr. Res. 68, 299–307.
Horan, W.P., Kring, A.M., Gur, R.E., Reise, S.P., Blanchard, J.J., 2011. Development and
psychometric validation of the Clinical Assessment Interview for Negative Symptoms
(CAINS). Schizophr. Res. 132, 140–145.
Kay, S.R., Opler, L.A., Fiszbein, A., 2006. The Positive and Negative Syndrome Technical
Manual, Multi-Health Systems Incorporated.
Kirkpatrick, B., Fenton, W.S., et al., 2006. The NIMH–MATRICS consensus statement on
negative symptoms. Schizophr. Bull. 32 (2), 214–219.
Kirkpatrick, B., Strauss, G., Nguyen, L., Fischer, B.A., Daniel, D.G., Cienfuegos, A., Marder,
S.R., 2011. The Brief Negative Symptom Scale: Psychometric Properties. Schizophr.
Bull. 37, 300–305.
Kring, A.M., Gur, R.E., Blanchard, J.J., Horan, W.P., Reise, S.P., 2013. Clinical Assessment
Interview for Negative Symptoms (CAINS): Final Development and Validation. Am.
J. Psychiatry 170 (2), 165–172 (Feb 1).
Levine, S.Z., Rabinowitz, J., 2007. Revisiting the 5 Dimensions of the Positive and
Negative Syndrome Scale. J. Clin. Psychopharmacol. 27 (5), 431–436.
Marder, S.R., Daniel, D.G., et al., 2011. Methodological issues in negative symptom trials.
Schizophr. Bull. 37 (2), 250–254.
Strauss, G.P., Keller, W.R., Buchanan, R.W., et al., 2012a. Next-generation negative
symptom assessment for clinical trials: Validation of the Brief Negative Symptom
Scale. Schizophr. Res. http://dx.doi.org/10.1016/j.schres.2012.10.012.
Strauss, G.P., Hong, L.E., Gold, J.M., et al., 2012b. Factor structure of the brief negative
symptom scale. Schizophr. Res. http://dx.doi.org/10.1016/j.schres.2012.09.007.
